U.S. markets closed

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
966.10+8.10 (+0.85%)
At close: 04:59PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close958.00
Bid965.50 x 0
Ask966.10 x 0
Day's Range956.40 - 969.50
52 Week Range620.70 - 976.30
Avg. Volume1,541,259
Market Cap2.135T
Beta (5Y Monthly)0.33
PE Ratio (TTM)39.53
EPS (TTM)24.44
Earnings DateMay 04, 2023
Forward Dividend & Yield11.15 (1.16%)
Ex-Dividend DateAug 12, 2022
1y Target Est968.52
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NOVO-B.CO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Novo Nordisk A/S - share repurchase programme

      Bagsværd, Denmark, 07 February 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programm

    • GlobeNewswire

      Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

      Bagsværd, Denmark, 7 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their

    • Zacks

      Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

      Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.